Simultaneous Improvement of Alopecia Universalis and Atopic Dermatitis in a Patient Treated with a JAK Inhibitor
June 2018
in “
JAAD case reports
”
New to Tofacitinib? There is a guide in the encyclopedia. Read the guide → Studysummary This article reviews the differences in inflammatory processes between alopecia universalis and atopic dermatitis, focusing on type 1 and type 2 immune responses, but it reports no new results.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
A 22-year-old man with alopecia universalis (AU) and moderately severe atopic dermatitis (AD) showed significant improvement in both conditions after 10 months of treatment with the JAK inhibitor tofacitinib. The patient, who had not responded to multiple previous treatments, experienced hair regrowth and reduced itch severity without adverse effects. This case highlighted the potential of tofacitinib to simultaneously treat multiple inflammatory skin disorders by inhibiting cytokine pathways involved in both AU and AD. The findings suggested a personalized medicine approach could be beneficial for managing complex inflammatory conditions.
